Clinical trials
Prostate Cancer Recurrent clinical trials
Below are recruiting prostate cancer recurrent clinical trials, each written for real people, not researchers. We’re tracking 237 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06696326Recruiting
New PET scan for prostate cancer detection
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Xiamen, FujianAges 18–90 - NCT07190300RecruitingPhase 1/Phase 2
Testing tulmimetostat with hormone therapy for metastatic prostate cancer
This trial tests a new drug, tulmimetostat, combined with standard hormone therapies like darolutamide or abiraterone for men with metastatic prostate cancer that still responds to hormone treatment. The goal is to see if the combination works better than standard therapy alone.
Birmingham, AlabamaAges 18 years+ - NCT05104515RecruitingPhase 1
First cancer vaccine test for advanced lung, ovarian, or prostate cancer
This Phase 1 study tests OVM-200, a new cancer vaccine, to see how it is tolerated and how it affects the immune system in people with advanced NSCLC, ovarian cancer, or prostate cancer. You may be eligible if your cancer has already had approved treatment(s) and no further standard options are planned within the first two months.
London, LondonAges 18–75 - NCT07699705Recruiting
Proton Beam Therapy for Localized Prostate Cancer
This study tests a very short course (ultrahypofractionated) of proton beam radiation for localized prostate cancer. It aims to see if it's safe and effective with fewer treatment visits.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT05593497RecruitingPhase 2
Study of hormone therapy plus capivasertib before prostate surgery
This Phase 2 trial tests whether adding capivasertib to intensified hormone therapy (leuprolide plus abiraterone) given before prostate surgery can improve outcomes for men with high-risk localized prostate cancer that has a specific tumor marker (PTEN loss). You would also have extra blood tests, scans, and a tissue biopsy for tumor testing.
West Los Angeles, CaliforniaAges 18 years+ - NCT07129551Recruiting
PSMA-guided surgery for prostate cancer with lymph node spread
This study looks at how well a special type of surgery, guided by PSMA-PET scans, works for men with prostate cancer that has spread to a small number of lymph nodes in the pelvis. It aims to improve outcomes and quality of life.
Hamburg, Free and Hanseatic City of HamburgAges 18–78 - NCT07197580RecruitingPhase 3
Study of a targeted radiation therapy for advanced kidney cancer
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Sydney, New South WalesAges 18 years+ - NCT07253987Recruiting
Cancer Survivors Program for Breast or Prostate Cancer
This study offers a program to help people who have completed their main treatment for early-stage breast or prostate cancer. It focuses on follow-up and support during survivorship, and you are still eligible if you are on certain maintenance therapies like hormone therapy.
BrnoAges 18 years+ - NCT06462495RecruitingEarly Phase 1
Comparing two PSMA PET/CT scans for prostate cancer
This trial compares two types of PET/CT scans (using different radioactive tracers) to see which is better at finding prostate cancer, tracking its return, or spotting spread. It's for people with prostate cancer or those being checked for recurrence after treatment.
Hefei, AnhuiAges 18–90 - NCT06462508RecruitingEarly Phase 1
Comparing two PET scans for prostate cancer detection
This trial compares two types of PET scans—one using a new tracer called [18F]F-PSMA-N5 and another using an existing tracer called [68Ga]Ga-PSMA-11—to see which is better at finding prostate cancer, including early signs of recurrence. If you have or are suspected of having prostate cancer, this study may help determine how advanced the disease is.
Hefei, AnhuiAges 18–90 - NCT06756334RecruitingEarly Phase 1
Comparing Two PET/CT Scans for Prostate Cancer
This study compares two types of PET/CT scans (using different radioactive tracers) to see which one is better at finding prostate cancer, detecting if it has come back, or spotting spread to other parts of the body. You will get both scans so doctors can compare them directly.
Hefei, AnhuiAges 18–90 - NCT03836196Recruiting
Improve treatment for advanced prostate cancer with careful planning
This study looks at how to best plan and deliver treatment for men with advanced local prostate cancer. It may help find the most effective approach while keeping side effects manageable.
Vancouver, British ColumbiaAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT05283330RecruitingPhase 1
Tested 212Pb imaging drug for certain advanced GRPR tumors
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Chicago, IllinoisAges 18 years+ - NCT07206056RecruitingPhase 1/Phase 2
Study of tulmimetostat and luxdegalutamide for advanced prostate cancer
This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.
Denver, ColoradoAges 18 years+ - NCT03459820Enrolling by invitationPhase 2/Phase 3
PET/CT scan study for high-risk or returning prostate cancer
This trial studies how a special PET/CT scan (using 18F-DCFPyL) helps evaluate prostate cancer that is either high-risk at diagnosis or has come back based on PSA blood tests. It may help your care team better stage (map) the cancer and guide next steps.
Montreal, QuebecAges 18 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT06594926RecruitingPhase 2
Bipolar androgen therapy for prostate cancer without metastases
This trial tests a treatment called bipolar androgen therapy for men with prostate cancer that has not spread to other parts of the body and is still growing despite taking darolutamide. The goal is to see if this therapy can help control the cancer.
Garran, Australian Capital TerritoryAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT07142967Recruiting
MR-Linac radiotherapy for prostate cancer that returned after earlier radiation
This trial tests if a special MRI-guided radiotherapy machine (MR-Linac) can safely treat prostate cancer that has come back after previous radiation therapy. It may help men who have limited options and want to avoid more invasive treatments.
New York, New YorkAges 18 years+ - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
Sarasota, FloridaAges 18 years+ - NCT07184970Recruiting
Detecting prostate cancer return after HIFU with advanced scans
This trial uses a special PET/MRI scan to check if prostate cancer has come back after high-intensity focused ultrasound (HIFU) treatment. It aims to find any remaining cancer early so doctors can plan next steps.
New York, New YorkAges 40–95 - NCT06689163RecruitingPhase 1/Phase 2
Study of HRS-1167 with abiraterone for metastatic prostate cancer
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
Hefei, AnhuiAges 18 years+ - NCT06926374Recruiting
Robotic surgery for gastrointestinal and urologic conditions
This trial tests a new robotic surgery system for common operations on the colon, rectum, prostate, kidney, bladder, stomach, esophagus, gallbladder, and hiatal hernia. It may offer a less invasive option for patients who need surgery for these conditions.
Hong KongAges 18–80
Hear when a new Prostate Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer recurrent?
- Yes. Clin2 currently lists 237 recruiting prostate cancer recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.